SCHEMBL3471734

SCHEMBL3471734

CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(=O)O)nn3-c3ccccc3Cl)s2)c1

nearest known ligand 0.81

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
RXRA P19793 7/20 0.81
NR1H2 P55055 7/20 0.81
NR1H3 Q13133 7/20 0.81
MARS1 P56192 3/20 0.47
ALDH1A1 P00352 1/20 0.47
ALOX5 P09917 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
CNR1 P21554 1/20 0.43
SLC16A3 O15427 1/20 0.42
SLC16A1 P53985 1/20 0.42
MCTS1 Q9ULC4 1/20 0.42
RPA1 P27694 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473473 0.92 RXRA (0.81) RXRANR1H2NR1H3MARS1ALDH1A1
SCHEMBL3472055 0.92 NR1H2 (0.81) RXRANR1H2NR1H3MARS1ALDH1A1
SCHEMBL14623269 0.90 RXRA (0.80) RXRANR1H2NR1H3MARS1CNR1
SCHEMBL3473692 0.90 RXRA (0.77) RXRANR1H2NR1H3MARS1ALDH1A1
SCHEMBL3470842 0.90 NR1H2 (0.77) RXRANR1H2NR1H3ALOX5PTGS1
SCHEMBL3470760 0.90 NR1H2 (1.00) RXRANR1H2NR1H3MAPTCNR1
SCHEMBL3471349 0.90 NR1H2 (0.77) RXRANR1H2NR1H3CNR1SLC16A3
SCHEMBL3474140 0.89 NR1H2 (0.73) RXRANR1H2NR1H3MARS1ALDH1A1
SCHEMBL3474075 0.88 NR1H2 (0.75) RXRANR1H2NR1H3CNR1SLC16A3
SCHEMBL3474072 0.88 NR1H2 (0.75) RXRANR1H2NR1H3CNR1SLC16A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
EP-1910307-A1 PYRAZOLE BASED LXR MODULATORS Exelixis, Inc. (US) 2008-04-16 EP disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed
WO-2007002559-A1 PYRAZOLE BASED LXR MODULATORS EXELIXIS, INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.